- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01050452
Safety and Efficacy of Drug Combinations Against Trichuris Trichiura
January 14, 2010 updated by: DBL -Institute for Health Research and Development
Gaps in Helminth Control: Safety and Efficacy of Drug Combinations. Study on Trichuris Trichiura.
This randomised, controlled, double-blinded clinical study investigates the safety and efficacy of albendazole (ALB), mebendazole (MBD) and ivermectin (IVM) separately, and ALB and MBD each in combination with IVM in the treatment of Trichuris trichiura in children aged 5-14 years.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
750
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Kampala, Uganda
- Vector Control Division
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
5 years to 15 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Those who are enrolled in class one to six
- Are infected with T. trichiura
- Whose parent consent and who are willing to participate
Exclusion Criteria:
- Those with acute and chronic diseases other than T. trichiura
- Those with a history of any serious adverse drug reactions
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: 1
albendazole treatment
|
albendazole (400 mg on dose)
|
Active Comparator: 2
mebendazole treatment
|
mebendazole (500 mg one dose)
|
Active Comparator: 3
ivermectin treatment
|
ivermectin (200 microgram/kg body weight)
|
Active Comparator: 4
albendazole + ivermectin treatment
|
albendazole (400 mg one dose) + ivermectin (200 mg microgram/kg body weight)
|
Active Comparator: 5
mebendazole + ivermectin treatment
|
mebendazole (500 mg one dose) + ivermectin (200 microgram/kg body weight)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Record adverse reactions
Time Frame: 6 weeks
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Efficacy of treatment
Time Frame: 6 weeks
|
6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2007
Primary Completion (Actual)
August 1, 2009
Study Completion (Actual)
August 1, 2009
Study Registration Dates
First Submitted
January 22, 2008
First Submitted That Met QC Criteria
January 14, 2010
First Posted (Estimate)
January 15, 2010
Study Record Updates
Last Update Posted (Estimate)
January 15, 2010
Last Update Submitted That Met QC Criteria
January 14, 2010
Last Verified
January 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Parasitic Diseases
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antiprotozoal Agents
- Antiparasitic Agents
- Antinematodal Agents
- Anthelmintics
- Antiplatyhelmintic Agents
- Anticestodal Agents
- Ivermectin
- Mebendazole
- Piperazine
- Piperazine citrate
- DMP 777
- Albendazole
Other Study ID Numbers
- AO.UGA.TRI
- DBL-CHRD
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parasitic Diseases
-
Sohag UniversityNot yet recruitingIntestinal Parasitic Infection
-
McGill University Health Centre/Research Institute...CompletedIntestinal Diseases, ParasiticPeru
-
Sohag UniversityNot yet recruiting
-
Al-Azhar UniversityCompleted
-
Nicolaus Copernicus UniversityCompletedChronic Disease | Intestinal Disease, ParasiticPoland
-
University of Colorado, DenverNo longer available
-
University of MalayaCompletedKnowledge, Attitudes, Practice | Intestinal Parasitic InfectionsMalaysia
-
Sohag UniversityRecruitingIrritable Bowel SyndromeEgypt
-
Mekelle UniversityUniversity of Alcala; Maastricht UniversityCompletedAnaemia | Intestinal Parasitic InfectionsEthiopia
-
McGill University Health Centre/Research Institute...McGill University; Canadian Institutes of Health Research (CIHR); World Health... and other collaboratorsCompletedIntestinal Diseases, Parasitic | MalnutritionPeru
Clinical Trials on albendazole
-
Washington University School of MedicineNational Public Health Institute of LiberiaNot yet recruitingOnchocerciasis | Onchocerciasis, Ocular | Tropical Disease | Onchocercal Subcutaneous Nodule | Onchocerca InfectionLiberia
-
London School of Hygiene and Tropical MedicineEmory UniversityTerminated
-
Universidad Nacional de SaltaFundacion Mundo SanoNot yet recruitingPharmacological Action
-
GlaxoSmithKlineCompleted
-
Centers for Disease Control and PreventionUniversidad del Valle, GuatemalaCompletedPediculosis | Strongyloidiasis | Ascariasis | Trichuriasis | Hookworm InfectionGuatemala
-
Navrongo Health Research Centre, GhanaDBL -Institute for Health Research and DevelopmentUnknownAnemia | Malaria | Helminthiasis | Schistosomiasis | Change in Sustained AttentionGhana
-
University GhentSwiss Tropical & Public Health InstituteCompletedSoil-transmitted Helminth InfectionsEthiopia, Lao People's Democratic Republic, Brazil, Tanzania
-
Washington University School of MedicineCompletedLymphatic Filariasis | Onchocerciasis | Soil Transmitted Helminth (STH) InfectionsCôte D'Ivoire
-
Swiss Tropical & Public Health InstitutePublic Health Laboratory Ivo de CarneriCompletedTrichuris Trichiura; InfectionTanzania